Publications by authors named "C Tankersley"

Claim this Profile
P
PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers.
Michael Hulse, Min Wang, Chaoyi Xu, Jack Carter, Anjana Agarwal, Chris Tankersley

Cancer Res· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings.
Steven P Treon, Camille N Kotton, David J Park, Giorgia Moranzoni, Camilla K Lemvigh, Christopher Tankersley

Front Immunol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.
Stephen Opat, Alessandra Tedeschi, Bei Hu, Kim M Linton, Pamela McKay, Chris Tankersley

Blood Adv· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.
Stephen Opat, Alessandra Tedeschi, Kim Linton, Pamela McKay, Bei Hu, Chris Tankersley

Clin Cancer Res· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Acute Effects of Age and Particulate Matter Exposure on Heart Rate and Heart Rate Variability in Mice.
Blake A Bennett, Ernst W Spannhake, Ana M Rule, Patrick N Breysse, Clarke G Tankersley

Cardiovasc Toxicol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis